盐酸替罗非班治疗急性冠脉综合征的研究

The efficacy and safety of tirofiban for acute coronary syndrome

目的:观察血小板糖蛋白(GP)Ⅱb/Ⅲa受体拮抗剂盐酸替罗非班治疗急性冠脉综合征(ACS)患者的效果。方法:60例ABC患者随机分为替罗非班组和对照组,前者给予常规治疗加替罗非班持续泵入36h,后者只给常规治疗。观察两组患者30d内心脏复合终点事件的发生率及出血的比例。结果:替罗非班组的心脏复合终点事件发生率明显低于对照组(P<0.05),两组出血的比例无显著差异。结论:盐酸替罗非班用于ACS患者效果显著且安全。

Objective：To observe the efficacy and safety of use of platelet glycoprotein Ⅱ b/Ⅲ a receptor antagonist （tirofiban） in acute coronary syndrome （ACS）. Methods： ACS patients who were randomly divided into tirofiban group and conventional treatment group. The incidence of the primary composite end point and the bleeding incidence were analyzed and compared between two groups. Results ：The incidence of the primary composite end point rates in tirofiban group were significantly lower than those in control group,with no differences in the bleeding incidence between two groups. Conclusions：The use of tirofiban is safe and significantly reduces the incidence of ischemic/thrombotic complications.